Delivery of corticosteroids directly into the eye is more effective than injections adjacent to the eye, according to results from a comparative clinical trial of macular edema in patients with noninfectious uveitis. The ...
Sep 27, 2018
0
74
Patients with uveitis, the fifth leading cause of vision loss in the United States, treated with either systemic anti-inflammatory medicine or with a time-release implant surgically placed inside the eye experienced a similar ...
Aug 19, 2011
0
0
University of Texas Medical Branch at Galveston researchers have discovered that a drug already prescribed to millions of people with diabetes could also have another important use: treating one of the world's leading causes ...
May 7, 2012
0
0
The acute outbreak of Ebola virus disease (EVD) has subsided in West Africa, but the medical community continues to learn about long-term complications for survivors – including the potential for blinding eye disease. One ...
Jan 16, 2017
0
1
The results of the largest retrospective study of multiple sclerosis (MS) in uveitis patients has revealed that nearly 60 percent of patients with both diseases were diagnosed with each within a five-year span. The study ...
Oct 20, 2014
0
0
A new study published in the current issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) suggests that the biologic agent adalimumab may be a viable treatment option for patients ...
Oct 22, 2013
0
0
Systemic therapy consisting of corticosteroids and immunosuppressants preserved vision of uveitis patients better - and had fewer adverse outcomes - than a long-lasting corticosteroid intraocular implant, according to a clinical ...
May 8, 2017
0
0
A team of researchers from the UCH CEU's Biomedical Sciences Institute has tested the efficiency of Bevacizumab, medicine used against cancer and in opthalmology, to treat uveítis, thus stopping the inflammation from spreading.
Oct 22, 2018
0
1
Scientists have developed a new RNA interference (RNAi) therapeutic agent that safely blocked ocular inflammation in mice, potentially making it a new treatment for human uveitis and diabetic retinopathy.
Feb 14, 2017
0
0
(HealthDay)—Soluble interleukin 2 receptor (sIL-2R) has slightly better diagnostic value than angiotensin-converting enzyme (ACE) for sarcoidosis in patients with uveitis, according to a study published online Nov. 9 in ...
Nov 13, 2017
0
0
